| Table 2: Indications for ERCP in guidewire and conventional therapy groups. |
| | Characteristics | Guidewire group () | Conventional group () |
| | Choledocholithiasis | 425 (77.8) | 136 (67.3) | | Cholangiocarcinoma | 31 (5.7) | 13 (6.4) | | Pancreatic head cancer | 33 (6.0) | 21 (10.4) | | Suspected sphincter of Oddi dysfunction | 138 (25.3) | 57 (28.2) | | Primary sclerosing cholangitis | 12 (2.2) | 15 (7.4) | | Others | 43 (7.9) | 15 (7.4) |
|
|
Data are presented as number (percentage).
|